Lukas Bunse
Mannheim, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications
Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.
Journal: Nature cancer
Published: August 03, 2026
Perspectives of Biophysical Therapies in Glioblastoma.
Journal: Brain stimulation
Published: March 06, 2026
Primary mismatch repair deficient glioma, IDH-wildtype and H3-wildtype: A giant cell tumor with potential for long-term survival occurring at all ages.
Journal: Neuro-oncology
Published: December 15, 2025
Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.
Journal: Neuro-oncology
Published: December 15, 2025
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.
Journal: Nature cancer
Published: October 30, 2025
Early distant progression in adult Histone-3 K27-altered diffuse midline gliomas.
Journal: Journal of neuro-oncology
Published: September 05, 2025
Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial.
Journal: Nature cancer
Published: August 22, 2025
Multimodality mapping of immunotherapy distribution as a predictive marker in glioma.
Journal: Neuro-oncology
Published: August 15, 2025
A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct.
Journal: Molecular therapy. Oncology
Published: August 04, 2025
ESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancer.
Journal: Journal for immunotherapy of cancer
Published: July 30, 2025
Last Updated: 09/26/2026